Literature DB >> 27249682

Collective Wisdom: Lobular Carcinoma of the Breast.

George W Sledge1, Anees Chagpar1, Charles Perou1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27249682     DOI： 10.1200/EDBK_100002

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


× No keyword cloud information.
  9 in total

1.  Integrated molecular analysis of Tamoxifen-resistant invasive lobular breast cancer cells identifies MAPK and GRM/mGluR signaling as therapeutic vulnerabilities.

Authors:  Hillary Stires; Mary M Heckler; Xiaoyong Fu; Zhao Li; Catherine S Grasso; Michael J Quist; Joseph A Lewis; Uwe Klimach; Alan Zwart; Akanksha Mahajan; Balázs Győrffy; Luciane R Cavalli; Rebecca B Riggins
Journal:  Mol Cell Endocrinol       Date:  2017-09-19       Impact factor: 4.102

2.  Invasive Lobular Carcinoma of the Breast With Rectal Metastasis: A Rare Case Report.

Authors:  Nada E Algethami; Amjad A Althagafi; Rawan A Aloufi; Fawaz A Al Thobaiti; Hamma A Abdelaziz
Journal:  Cureus       Date:  2022-03-30

Review 3.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

4.  Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.

Authors:  Harriet T Rothschild; Mary Kathryn Abel; Anne Patterson; Kent Goodman; Amy Shui; Karen van Baelen; Christine Desmedt; Christopher Benz; Rita A Mukhtar
Journal:  Breast Cancer Res Treat       Date:  2021-11-24       Impact factor: 4.624

Review 5.  Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

Authors:  George Sflomos; Koen Schipper; Thijs Koorman; Amanda Fitzpatrick; Steffi Oesterreich; Adrian V Lee; Jos Jonkers; Valerie G Brunton; Matthias Christgen; Clare Isacke; Patrick W B Derksen; Cathrin Brisken
Journal:  Cancers (Basel)       Date:  2021-10-27       Impact factor: 6.639

6.  Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?

Authors:  Mary Kathryn Abel; Michelle E Melisko; Hope S Rugo; A Jo Chien; Italia Diaz; Julia K Levine; Ann Griffin; Joseph McGuire; Laura J Esserman; Hala T Borno; Rita A Mukhtar
Journal:  NPJ Breast Cancer       Date:  2021-10-25

7.  The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.

Authors:  Mary Kathryn Abel; Amy M Shui; Michelle Melisko; A Jo Chien; Emi J Yoshida; Elizabeth M Lancaster; Laura Van 't Veer; Laura J Esserman; Rita A Mukhtar
Journal:  NPJ Breast Cancer       Date:  2021-12-21

8.  The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.

Authors:  Mary Kathryn Abel; Amy M Shui; A Jo Chien; Hope S Rugo; Michelle Melisko; Frederick Baehner; Rita A Mukhtar
Journal:  Ann Surg Oncol       Date:  2022-07-09       Impact factor: 4.339

9.  Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.

Authors:  Mary Kathryn Abel; Case E Brabham; Ruby Guo; Kelly Fahrner-Scott; Jasmine Wong; Michael Alvarado; Cheryl Ewing; Laura J Esserman; Rita A Mukhtar
Journal:  Am J Surg       Date:  2020-06-19       Impact factor: 2.565
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.